RenovoRx (NASDAQ:RNXT – Get Free Report) and SeaStar Medical (NASDAQ:ICU – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.
Insider & Institutional Ownership
3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by company insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and price targets for RenovoRx and SeaStar Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RenovoRx | 1 | 0 | 2 | 1 | 2.75 |
| SeaStar Medical | 1 | 0 | 1 | 0 | 2.00 |
RenovoRx currently has a consensus price target of $8.50, suggesting a potential upside of 802.34%. SeaStar Medical has a consensus price target of $8.00, suggesting a potential upside of 755.61%. Given RenovoRx’s stronger consensus rating and higher probable upside, equities analysts plainly believe RenovoRx is more favorable than SeaStar Medical.
Profitability
This table compares RenovoRx and SeaStar Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RenovoRx | -469.02% | -133.49% | -101.50% |
| SeaStar Medical | -678.24% | -261.10% | -149.15% |
Earnings and Valuation
This table compares RenovoRx and SeaStar Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RenovoRx | $1.12 million | 40.58 | -$11.17 million | ($0.31) | -3.04 |
| SeaStar Medical | $1.23 million | 4.04 | -$12.15 million | ($3.64) | -0.26 |
RenovoRx has higher earnings, but lower revenue than SeaStar Medical. RenovoRx is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
RenovoRx has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.07, meaning that its stock price is 207% less volatile than the S&P 500.
Summary
RenovoRx beats SeaStar Medical on 13 of the 14 factors compared between the two stocks.
About RenovoRx
RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body. The company’s platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.
About SeaStar Medical
SeaStar Medical Holding Corp. is a medical technology company developing extracorporeal therapies intended to address harmful inflammation in patients with critical illnesses. Its approach uses the Selective Cytopheretic Device (SCD), which processes blood outside the body and is designed to target activated immune cells associated with inflammation. The company’s lead product, QUELIMMUNE, is an SCD-based therapy for certain pediatric patients with acute kidney injury and sepsis or a septic condition who require continuous kidney replacement therapy.
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
